

# Valovir®

Valacyclovir Hydrochloride Tablet

## Presentation

Valovir® 500 Tablet: Each tablet contains Valacyclovir Hydrochloride INN equivalent to Valacyclovir 500 mg.

Valovir® 1 gm Tablet: Each tablet contains Valacyclovir Hydrochloride INN equivalent to Valacyclovir 1 gm.

## Description

Valacyclovir Hydrochloride is a nucleoside analogue DNA polymerase inhibitor. It is rapidly converted to Acyclovir which has demonstrated antiviral activity against HSV types 1 (HSV-1) and 2 (HSV-2) and VZV. Viral enzyme converts Acyclovir to Acyclovir Triphosphate which inhibits viral DNA synthesis.

## Indications and Uses

### Adult Patients

- Cold Sores (Herpes Labialis)
- Genital Herpes
  - Treatment in immunocompetent patients (initial or recurrent episode)
  - Suppression in immunocompetent or HIV-infected patients
  - Reduction of transmission
- Herpes Zoster

### Paediatric Patients

- Cold Sores (Herpes Labialis)
- Chickenpox

## Dosage and Administration

### Adult Dosage

Cold Sores	2 grams every 12 hours for 1 day
Genital Herpes	
Initial episode	1 gram twice daily for 10 days
Recurrent episodes	500 mg twice daily for 3 days
Suppressive therapy	
Immunocompetent patients	1 gram once daily
Alternate dose in patients with $\leq 9$ recurrences/yr	500 mg once daily
HIV-infected patients	500 mg twice daily
Reduction of transmission	500 mg once daily
Herpes Zoster	1 gram 3 times daily for 7 days

### Pediatric Dosage

Cold Sores ( $\geq 12$ years of age)	2 grams every 12 hours for 1 day
Chickenpox (2 to $< 18$ years of age)	20 mg/kg 3 times daily for 5 days; not to exceed 1 gram 3 times daily

## Side Effects

The most common adverse reactions reported in at least one indication by  $>10\%$  of adult patients treated with Valacyclovir Hydrochloride and more commonly than in patients treated with placebo are headache, nausea, and abdominal pain.

The only adverse reaction occurring in  $>10\%$  of paediatric patients  $<18$  years of age was headache.

## Precautions

Dosage reduction is recommended when administering Valacyclovir to patients with renal impairment. Similar caution should be exercised when administering Valacyclovir to geriatric patients (over 65 years), and patients receiving potentially nephrotoxic agents. The safety and efficacy of Valacyclovir have not been established in immuno-compromised patients other than for the suppression of genital herpes in HIV-infected patients.

## Use in Pregnancy & Lactation

### Pregnancy

Pregnancy Category B. Valacyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### Lactation

Very small amounts of Valacyclovir are excreted in human milk. Therefore, Valovir® can be given to the lactating mothers. But caution should be exercised when administered to them.

## Contraindications

Hypersensitivity to Valacyclovir, Acyclovir, or any component of the formulation.

## Drug Interactions

No clinically significant drug-drug or drug-food interactions with Valacyclovir are known.

## Overdosage


Caution should be exercised to prevent inadvertent overdose.

## Commercial Pack

Valovir® 500 tablet: Each box contains 1 blister strip of 10 tablets.

Valovir® 1 gm tablet: Each box contains 4 blister strips of 2 tablets.

Manufactured by

 **Incepta Pharmaceuticals Ltd**

Savar, Dhaka, Bangladesh

® Registered Trademark

V.N.02

VL5